Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

08-272021

Bio-Thera Solutions and Hikma Pharmaceuticals announce exclusive commercialization and license agreement for BAT2206 in the US, a proposed biosimilar referencing Stelara® (ustekinumab)

Guangzhou and London, 27 August2021–Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today...
08-122021

Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, tod...
06-092021

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)

Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, to...

上一页 ···22 23 24 25 26 ··· 下一页